173 related articles for article (PubMed ID: 36989239)
1. Axl contributes to efficient migration and invasion of melanoma cells.
Shao H; Teramae D; Wells A
PLoS One; 2023; 18(3):e0283749. PubMed ID: 36989239
[TBL] [Abstract][Full Text] [Related]
2. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
3. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
4. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
[TBL] [Abstract][Full Text] [Related]
5. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
6. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
7. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
[TBL] [Abstract][Full Text] [Related]
8. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
[TBL] [Abstract][Full Text] [Related]
9. Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.
Revach OY; Sandler O; Samuels Y; Geiger B
Cancer Res; 2019 May; 79(10):2634-2648. PubMed ID: 30914429
[TBL] [Abstract][Full Text] [Related]
10. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
Al Kafri N; Hafizi S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
[TBL] [Abstract][Full Text] [Related]
12. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
13. TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Schmitz R; Valls AF; Yerbes R; von Richter S; Kahlert C; Loges S; Weitz J; Schneider M; Ruiz de Almodovar C; Ulrich A; Schmidt T
Oncotarget; 2016 Aug; 7(35):56355-56370. PubMed ID: 27486820
[TBL] [Abstract][Full Text] [Related]
14. Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.
Shao H; Wang A; Lauffenburger D; Wells A
Int J Biochem Cell Biol; 2018 Feb; 95():73-84. PubMed ID: 29274473
[TBL] [Abstract][Full Text] [Related]
15. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
16. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
18. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Seitz HM; Camenisch TD; Lemke G; Earp HS; Matsushima GK
J Immunol; 2007 May; 178(9):5635-42. PubMed ID: 17442946
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
[TBL] [Abstract][Full Text] [Related]
20.
Saito T; Itoh M; Tohda S
Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
